Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape

Viruses. 2020 Oct 28;12(11):1223. doi: 10.3390/v12111223.

Abstract

HIV-1 cure strategy by means of proviral knock-out using CRISPR-Cas9 has been hampered by the emergence of viral resistance against the targeting guide RNA (gRNA). Here, we proposed multiple, concentrated gRNA attacks against HIV-1 regulatory genes to block viral escape. The T cell line were transduced with single and multiple gRNAs targeting HIV-1 tat and rev using lentiviral-based CRISPR-Cas9, followed by replicative HIV-1NL4-3 challenge in vitro. Viral p24 rebound was observed for almost all gRNAs, but multiplexing three tat-targeting gRNAs maintained p24 suppression and cell viability, indicating the inhibition of viral escape. Multiplexed tat gRNAs inhibited acute viral replication in the 2nd round of infection, abolished cell-associated transmission to unprotected T cells, and maintained protection through 45 days, post-infection (dpi) after a higher dose of HIV-1 infection. Finally, we describe here for the first time the assembly of all-in-one lentiviral vectors containing three and six gRNAs targeting tat and rev. A single-vector tat-targeting construct shows non-inferiority to the tat-targeting multi-vector in low-dose HIV-1 infection. We conclude that Cas9-induced, DNA repair-mediated mutations in tat are sufficiently deleterious and deplete HIV-1 fitness, and multiplexed disruption of tat further limits the possibility of an escape mutant arising, thus elevating the potential of CRISPR-Cas9 to achieve a long-term HIV-1 cure.

Keywords: CRISPR-Cas; HIV-1; cure; tat; viral escape.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems*
  • Cell Line
  • Gene Editing
  • Genetic Vectors
  • Genome, Viral
  • HIV-1 / immunology*
  • HIV-1 / physiology
  • Humans
  • Lentivirus / genetics
  • Mutation
  • Proviruses / genetics
  • RNA, Guide, CRISPR-Cas Systems / genetics*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / virology*
  • Virus Replication / genetics
  • tat Gene Products, Human Immunodeficiency Virus / antagonists & inhibitors
  • tat Gene Products, Human Immunodeficiency Virus / genetics*

Substances

  • RNA, Guide, CRISPR-Cas Systems
  • tat Gene Products, Human Immunodeficiency Virus